Australian radiopharmaceutical specialist Telix has revealed the terms of its planned initial public offering (IPO) in the US, revealing that it hopes to raise $202 millio
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
